Myriad Genetics MYGN Institutional Ownership

Updated Oct 21, 2026

Myriad Genetics Inc (NASDAQ:MYGN) counted 195 institutional investors among its 13F-reported shareholders for the quarter ended June 30, 2026.

• These investors owned 92.95% of Myriad Genetics' outstanding stock in Q2 2026.
• Total shares held in MYGN rose 0.91% from Q1 2026; the number of holders fell 11.36% from Q2 2025.
• Of the 195 holders, 119 added to their positions, 57 reduced their stakes and 19 left their positions unchanged in Q2 2026.
• In total, institutional investors held 88.86Mn shares of Myriad Genetics at the end of Q2 2026, up 803.13K from the prior quarter and up 4.57Mn from a year earlier.
• As of June 30, 2026, the biggest holder of Myriad Genetics was BlackRock, Inc. with 10.89Mn shares, or 11.39% of shares outstanding.
• The biggest increases in MYGN positions during Q2 2026 came from Vestal Point Capital, LP (+4.09Mn shares), BlackRock, Inc. (+2Mn shares), Citadel Advisors LLC (+1.08Mn shares), AQR Capital Management LLC (+854.39K shares) and Acadian Asset Management LLC (+818.38K shares).
• The largest position reductions in MYGN for Q2 2026 were by HRT Financial LP (-1.24Mn shares), Point72 Asset Management, L.P. (-719.12K shares), Morgan Stanley (-687.64K shares), Assenagon Asset Management S.A. (-415.5K shares) and UBS Group AG (-408.82K shares).
• Myriad Genetics' 10 largest institutional shareholders as of Q2 2026 were BlackRock, Inc. (10.89Mn shares), Millennium Management LLC (6.62Mn shares), Vestal Point Capital, LP (5.74Mn shares), State Street Corp (4.99Mn shares), D. E. Shaw & Co., Inc. (4.58Mn shares), Vanguard Capital Management LLC (4.08Mn shares), Acadian Asset Management LLC (3.13Mn shares), Vanguard Portfolio Management LLC (3.08Mn shares), AQR Capital Management LLC (2.77Mn shares) and Morgan Stanley (2.48Mn shares), per Business Quant data.